The Role of duodenal jejunal bypass liner in obesity treatment

IF 0.4 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Taha Gökmen Ülger, M. Tayfur, F. Çakıroğlu, Çig̃dem Özcan
{"title":"The Role of duodenal jejunal bypass liner in obesity treatment","authors":"Taha Gökmen Ülger, M. Tayfur, F. Çakıroğlu, Çig̃dem Özcan","doi":"10.3934/medsci.2021019","DOIUrl":null,"url":null,"abstract":"Endoscopic bariatric procedures including Duedenal Jejunal Bypass Liner (DJBL) have become widespread in obesity treatment in recent years. The aim of this systematic review was to assess the role of DJBL in obesity treatment. A comprehensive search of several databases, including Cochrane Library, PubMed, and Web of Science was conducted to December 2020. Twenty-four clinical studies were assessed. According to the results, it is clear that DJBL provides effective weight reduction at 6–12 months and significant improvements in parameters associated with metabolic syndrome and cardiovascular disease. This technique also has potential to reduce comedications in patients with obesity and type 2 diabetes. Although these positive effects of DJBL are clear, its effect on liver, pancreatic functions, and inflammation markers are not clear yet. In addition, the overall and serious complication (gastrointestinal bleeds, pancreatitis, hepatic abscess, obstruction of the sleeve, biliary colic without cholecystitis and cholangitis) rate causing from the DJBL is very high. DJBL has not been approved by the Food and Drug Administration due to the frequency and severity of complications it causes. While it is certain that DJBL has significant effects on obesity and obesity related comorbidities, the safety aspect needs to be improved.","PeriodicalId":43011,"journal":{"name":"AIMS Medical Science","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIMS Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3934/medsci.2021019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Endoscopic bariatric procedures including Duedenal Jejunal Bypass Liner (DJBL) have become widespread in obesity treatment in recent years. The aim of this systematic review was to assess the role of DJBL in obesity treatment. A comprehensive search of several databases, including Cochrane Library, PubMed, and Web of Science was conducted to December 2020. Twenty-four clinical studies were assessed. According to the results, it is clear that DJBL provides effective weight reduction at 6–12 months and significant improvements in parameters associated with metabolic syndrome and cardiovascular disease. This technique also has potential to reduce comedications in patients with obesity and type 2 diabetes. Although these positive effects of DJBL are clear, its effect on liver, pancreatic functions, and inflammation markers are not clear yet. In addition, the overall and serious complication (gastrointestinal bleeds, pancreatitis, hepatic abscess, obstruction of the sleeve, biliary colic without cholecystitis and cholangitis) rate causing from the DJBL is very high. DJBL has not been approved by the Food and Drug Administration due to the frequency and severity of complications it causes. While it is certain that DJBL has significant effects on obesity and obesity related comorbidities, the safety aspect needs to be improved.
十二指肠空肠旁路手术在肥胖症治疗中的作用
近年来,包括Duedenal空肠旁路手术(DJBL)在内的内镜下减肥手术在肥胖治疗中已得到广泛应用。本系统综述的目的是评估DJBL在肥胖治疗中的作用。到2020年12月,对包括Cochrane Library、PubMed和Web of Science在内的几个数据库进行了全面搜索。共评估了24项临床研究。根据结果,很明显,DJBL在6-12个月时有效减轻体重,并显著改善与代谢综合征和心血管疾病相关的参数。这项技术也有可能减少肥胖和2型糖尿病患者的药物治疗。虽然DJBL的这些积极作用是明确的,但其对肝脏、胰腺功能和炎症标志物的影响尚不清楚。此外,DJBL引起的全面和严重的并发症(胃肠道出血、胰腺炎、肝脓肿、套筒梗阻、无胆囊炎的胆绞痛和胆管炎)发生率很高。由于DJBL引起的并发症的频率和严重程度,它尚未获得食品和药物管理局的批准。虽然DJBL对肥胖和肥胖相关的合并症有显著的影响是肯定的,但安全性方面需要改进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
AIMS Medical Science
AIMS Medical Science MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
14.30%
发文量
20
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信